Calidi Biotherapeutics, Inc. Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Calidi Biotherapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2023-09-30 was $9.60M.
- Calidi Biotherapeutics, Inc. stock issued during period, value, conversion of units for fiscal 2023 was $9.60M.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2023-12-31 | $9.60M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $9.60M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |